Update: Starting the new year on a solid footing
Achillion brings in the new year well positioned, with the announcement of encouraging data from two of its hepatitis C compounds in late December enabling the start of combination trials for a potent all-oral duet in 2015. Each new positive data set adds value to the pipeline, increasing the potential of the company in any possible corporate partnership. The emergence of a novel factor D inhibitor platform (posters presented at ASH in December) underscores the scope of Achillion’s technology and its in-house abilities beyond that of its high-profile hepatitis C programme.Achillion Pharmaceuticals is a biopharmaceutical company. The company is engaged in the discovery and development of small molecule drug therapies for immune system disorders. The company is advancing orally administered small molecules from its platform that target complement factor D, an essential protein of the alternative pathway. The alternative pathway plays a role in a number of disease conditions, including therapeutic areas of nephrology, hematology, ophthalmology and neurology. Initially Co. is targeting C3 glomerulopathy, and immune complex membranoproliferative glomerulonephritis, two related rare diseases affecting the kidney, and paroxysmal nocturnal hemoglobinuria, a blood disorder.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.